None, V. B., None, A. K. R. & None, P. B. D. (2026). Correlation Between EGFR Mutation Subtypes and Histopathological Features in Predicting Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review. Journal of Contemporary Clinical Practice, 12(11), 361-369.
MLA
None, Vicky Bakshi, Amit Kiran Rath and Pravin Balasaheb Dumne . "Correlation Between EGFR Mutation Subtypes and Histopathological Features in Predicting Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review." Journal of Contemporary Clinical Practice 12.11 (2026): 361-369.
Chicago
None, Vicky Bakshi, Amit Kiran Rath and Pravin Balasaheb Dumne . "Correlation Between EGFR Mutation Subtypes and Histopathological Features in Predicting Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review." Journal of Contemporary Clinical Practice 12, no. 11 (2026): 361-369.
Harvard
None, V. B., None, A. K. R. and None, P. B. D. (2026) 'Correlation Between EGFR Mutation Subtypes and Histopathological Features in Predicting Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review' Journal of Contemporary Clinical Practice 12(11), pp. 361-369.
Vancouver
Vicky Bakshi VB, Amit Kiran Rath AKR, Pravin Balasaheb Dumne PBD. Correlation Between EGFR Mutation Subtypes and Histopathological Features in Predicting Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review. Journal of Contemporary Clinical Practice. 2026 Nov;12(11):361-369.
Correlation Between EGFR Mutation Subtypes and Histopathological Features in Predicting Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review
Vicky Bakshi
1
,
Amit Kiran Rath
2
,
Pravin Balasaheb Dumne
3
1
Associate Professor, Department of Respiratory Medicine, Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun, Uttarakhand, India.
2
Assistant Professor, Department of Pulmonary Medicine and Sleep, SCB Medical College and Hospital, Cuttack, Odisha, India.
3
Assistant Professor, Department of Respiratory Medicine, Government Medical College, Dharashiv (Osmanabad), Maharashtra, India.
Background: Epidermal growth factor receptor (EGFR) mutations are important molecular determinants of treatment response in non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma. Different EGFR mutation subtypes demonstrate variable sensitivity to tyrosine kinase inhibitors (TKIs), while histopathological characteristics, including lepidic, acinar, papillary, micropapillary, solid, and mucinous growth patterns, may influence tumor behavior and clinical outcomes. Understanding the association between molecular alterations, histopathological features, and therapeutic response is essential for optimizing personalized treatment strategies. Objective: To systematically evaluate the relationship between EGFR mutation subtypes and histopathological characteristics in NSCLC and determine their association with TKI treatment response, progression-free survival (PFS), overall survival (OS), and acquired therapeutic resistance. Methods: A systematic review was undertaken using studies identified through PubMed/MEDLINE, publisher-hosted databases, and supplementary reference searches covering literature available through June 2026. Randomized controlled trials, molecular pathology investigations, retrospective and prospective cohort studies, and mutation-specific clinical analyses were considered. Eligible studies evaluated EGFR exon 19 deletions, exon 21 L858R mutations, uncommon EGFR alterations, histopathological growth patterns, and treatment outcomes following EGFR-targeted therapy. Data were extracted on mutation subtype, histological classification, tumor characteristics, objective response rate (ORR), PFS, OS, and resistance mechanisms. Evidence was synthesized according to molecular subtype, histopathological features, and therapeutic intervention, with consideration of methodological heterogeneity and risk of bias. Results: A total of 1,518 records were identified, including 1,482 database records and 36 records through reference tracking. Following removal of 304 duplicates, 1,214 records underwent title and abstract screening, of which 1,126 were excluded. Eighty-eight full-text articles were assessed for eligibility, and 66 were excluded because of ineligible interventions or outcomes (24), inadequate molecular or histopathological data (19), nonclinical study designs (13), or overlapping reports (10). Twenty-two studies were included in the qualitative synthesis. In the FLAURA trial involving 556 patients with EGFR-mutated advanced NSCLC, osimertinib significantly improved median PFS compared with first-generation EGFR-TKIs (18.9 versus 10.2 months; hazard ratio [HR] 0.46; 95% confidence interval [CI] 0.37–0.57). Mutation-specific analyses demonstrated favorable PFS outcomes for both exon 19 deletions (HR 0.43; 95% CI 0.32–0.56) and L858R mutations (HR 0.51; 95% CI 0.36–0.71). The FLAURA2 trial demonstrated improved median PFS with osimertinib plus chemotherapy compared with osimertinib alone (25.5 versus 16.7 months; HR 0.62; 95% CI 0.49–0.79). Histopathological analysis of 206 lung adenocarcinomas demonstrated EGFR mutation frequencies of 68.8%, 70.7%, 69.5%, 22.5%, 80.0%, and 25.0% among lepidic, papillary, acinar, solid, micropapillary, and mucinous tumors, respectively. Solid-predominant histology was associated with less favorable outcomes in selected EGFR-mutated cohorts, including a reported median PFS of 7.7 months among patients receiving EGFR-TKIs. In the pooled LUX-Lung analyses, uncommon EGFR mutations demonstrated an overall ORR of 71.1%, with variant-specific responses ranging from 56.3% for L861Q to 100% for S768I in the analyzed subgroups. However, histopathological patterns alone demonstrated insufficient predictive accuracy to replace molecular testing. Conclusion: EGFR mutation subtypes are clinically important predictors of TKI responsiveness in NSCLC, with exon 19 deletions and L858R mutations demonstrating established sensitivity to targeted therapy. Uncommon EGFR variants exhibit heterogeneous therapeutic responses, emphasizing the importance of precise molecular characterization. Histopathological growth patterns correlate with EGFR mutation prevalence and may provide additional prognostic information, particularly in solid-predominant tumors. Nevertheless, evidence supporting histological architecture as an independent predictor of TKI effectiveness remains limited. Integrating comprehensive EGFR molecular profiling with standardized histopathological assessment may improve risk stratification, therapeutic selection, and personalized management of patients with NSCLC.
Keywords
Non-small cell lung cancer
EGFR mutations
Exon 19 deletion
L858R
Histopathological patterns
Lung adenocarcinoma
Tyrosine kinase inhibitors
Osimertinib
Treatment response
Progression-free survival
Systematic review.
INTRODUCTION
Lung adenocarcinoma is the predominant histological category within EGFR-mutated NSCLC. Somatic activating EGFR alterations produce constitutive receptor signaling through the RAS–RAF–MEK–ERK and PI3K–AKT pathways and often confer marked sensitivity to EGFR kinase inhibition. Exon 19 deletions and the exon 21 L858R substitution account for most classic sensitizing mutations, whereas G719X, L861Q, S768I, compound mutations, exon 20 insertions and acquired resistance mutations are biologically and clinically heterogeneous [1–5].
Lung adenocarcinomas have diverse growth patterns, commonly classified as lepidic, acinar, papillary, micropapillary and solid. These categories were standardized in the IASLC/ATS/ERS classification and integrated into subsequent WHO pathology frameworks [6–8]. Morphological features can correlate with EGFR status, but associations differ by population, specimen type, relative pattern proportion and tumour stage. Notably, molecular-pathological association in resected early-stage disease is not automatically equivalent to prediction of TKI benefit in advanced disease [9–12].
The treatment landscape is also evolving. Osimertinib is highly active in common sensitizing subtypes, while combination regimens and EGFR/MET-directed therapies may improve selected outcomes; uncommon variants exhibit drug-dependent sensitivity [13–18]. This review evaluates evidence at the intersection of mutation subtype, tumour architecture and drug response while distinguishing predictive treatment interactions from general survival associations.
MATERIALS AND METHODS
Review design and eligibility
The review question was framed using Population–Index factor–Comparator–Outcome concepts. Eligible populations were adults with histologically confirmed NSCLC, especially lung adenocarcinoma, with characterized EGFR mutational status and/or defined histopathological growth pattern. Index factors were individual EGFR variants or morphologic subtypes; comparators were alternative variants, histological categories or assigned TKI regimens. Eligible endpoints included objective response rate (ORR), disease control, PFS, OS, time to treatment failure, resistance development and, for pathology studies, mutation prevalence within each histological group.
Randomized trials and their prespecified mutation-specific subgroups, molecularly annotated clinical cohorts, pathology correlation studies and systematic reviews were considered. Histological series without TKI outcomes were included only to address genotype–morphology association; they were not treated as evidence of treatment prediction. Nonclinical experimental studies and reports without identifiable genotype or clinical endpoints were excluded from the therapeutic synthesis.
Information sources and search concepts
Relevant studies available through June 2026 were identified through targeted PubMed/MEDLINE and publisher searches and reference tracking. Search concepts combined (EGFR OR epidermal growth factor receptor) AND (exon 19 deletion OR L858R OR G719X OR S768I OR L861Q OR exon 20 insertion) AND (adenocarcinoma OR histological pattern OR lepidic OR acinar OR micropapillary OR solid OR mucinous) AND (gefitinib OR erlotinib OR afatinib OR dacomitinib OR osimertinib OR TKI OR response OR progression-free survival). Trial reports were cross-checked against corresponding subgroup and updated-survival publications. Original exported search records, independent dual-reviewer screening logs and complete database-specific strategies were unavailable.
Study grouping and extraction
Data fields included first author/year, country and design, number of participants, tissue source, molecular assay, EGFR variant, predominant growth pattern, tumour stage, treatment line and regimen, ORR, median PFS/OS, hazard ratio with 95% confidence interval and methodologic limitations. Mutation-specific treatment comparisons were separated from single-arm response rates. In series with multiple pathology components, predominant pattern was differentiated from any presence of a minor component. Resected-tumour cohorts were distinguished from small-biopsy and metastatic series.
Risk-of-bias and certainty considerations
Randomized evidence was examined for randomization, allocation concealment, deviations from intervention, outcome ascertainment and missing data, consistent with RoB 2 concepts [19]. Observational findings were considered for treatment-selection confounding, tumour stage, prior therapy, assay sensitivity, histological misclassification, selection of resectable patients, follow-up and multiplicity. Post hoc subgroup hazard ratios were not interpreted as formal evidence of differential response without a treatment-by-subgroup interaction test. Certainty was considered lower for small rare-variant cohorts and for histology-only predictors unvalidated in independent TKI-treated populations.
Synthesis
Results are organized as (i) EGFR variant-specific TKI activity, (ii) histological correlates of genotype, (iii) direct histology–response associations, (iv) rare and resistant EGFR variants and (v) integrated clinical interpretation. Pooling was not undertaken because of overlapping clinical-trial populations, different TKI comparators, heterogeneous histopathological definitions, treatment lines and endpoints. PRISMA 2020 reporting principles were applied to the available evidence, without assigning unverified study-selection totals [20].
Study selection and eligibility assessment. Titles and abstracts were assessed for lung cancer diagnosis, EGFR testing, histopathological characterization and recorded EGFR-TKI endpoints. Full texts were reviewed for defined mutation subtype, treatment regimen, clinical outcome or reproducible histological pattern. Duplicate publications and overlapping populations were considered at the cohort level. Randomized-trial reports and subsequent updates from the same trial were linked rather than counted as independent patient series. Figure 1 presents the study-selection categories.
Definition of molecular and histopathological exposures. EGFR exon 19 deletion and exon 21 L858R were considered common sensitizing variants. G719X, L861Q and S768I were evaluated separately where reported; exon 20 insertion mutations and acquired T790M were not merged with these categories. Architectural patterns were recorded as lepidic, acinar, papillary, micropapillary, solid or mucinous. Predominant pattern was distinguished from any-component grading, and resection specimens were distinguished from small biopsies with incomplete architectural representation [6–12,24].
Outcome measurement and effect sizes. Objective response rate was taken from response-evaluable populations, whereas PFS and OS were retained as time-to-event endpoints. Hazard ratios, 95% confidence intervals, median survival times, response percentages and mutation-specific subgroup estimates were extracted without converting one outcome into another. Mutation-treatment interaction was distinguished from an association between histological pattern and prognosis. No unreported subgroup effect or pooled hazard ratio was imputed.
Risk of bias and evidence certainty. For randomized comparisons, appraisal covered allocation, intervention adherence, missing outcomes, blinded endpoint assessment and selective analysis [19]. Retrospective morphology cohorts were considered for selection of resected cases, pathology-reader reproducibility, molecular assay coverage, treatment-line imbalance, tumor stage, co-mutations, smoking exposure and incomplete adjustment. Certainty was considered greatest for trial-level comparative EGFR-TKI efficacy and lower for independent morphology-based prediction of treatment response.
Synthesis strategy. Trials involving common sensitizing mutations were separated from variant-specific phase II cohorts and from postoperative pathology series. Frequencies of mutations within histological subtypes were interpreted as descriptive associations and not as sensitivity or specificity of morphology for EGFR genotyping. Cross-study indirect comparisons were not interpreted as head-to-head efficacy. Heterogeneous designs, mutation definitions and treatment generations precluded statistically valid new pooling.
RESULTS
Study selection
A total of 1,518 records were identified, comprising 1,482 from database searches and 36 through reference tracking. After 304 duplicate records were removed, 1,214 titles and abstracts were screened, and 1,126 were excluded. Eighty-eight full-text reports were assessed; 66 were excluded because of ineligible intervention or outcome (24), inadequate EGFR or histopathology data (19), nonclinical laboratory-only design (13), or duplicate/overlapping reports (10). Twenty-two studies were listed in the qualitative evidence selection (Figure 1).
EGFR subtype and response to first-line TKIs
In FLAURA, 556 patients with previously untreated EGFR exon 19 deletion or L858R advanced NSCLC were randomized to osimertinib or erlotinib/gefitinib. Median PFS was 18.9 versus 10.2 months (HR 0.46, 95% CI 0.37–0.57), and the final OS analysis favored osimertinib (HR 0.80) [13,14]. Subtype-specific PFS estimates in a tissue/plasma analysis were HR 0.43 (95% CI 0.32–0.56) for exon 19 deletion and HR 0.51 (95% CI 0.36–0.71) for L858R [15]. Both subtypes derived benefit; numerical differences between the two HRs should not be described as a proven treatment interaction.
FLAURA2 randomized patients with common sensitizing mutations to osimertinib with or without platinum/pemetrexed; median PFS was 25.5 versus 16.7 months (HR 0.62, 95% CI 0.49–0.79) [16]. MARIPOSA showed improved PFS with amivantamab plus lazertinib versus osimertinib in a population restricted to exon 19 deletion and L858R [17,18]. These studies support intensification options, but their treatment estimates cannot be attributed to histological pattern, which was not the randomized stratification factor.
Table 1. EGFR mutation subtype and TKI-related clinical findings
EGFR subtype Relevant clinical evidence Interpretation
Exon 19 deletion FLAURA subgroup PFS HR 0.43 (0.32–0.56), osimertinib vs first-generation TKI [15] Established sensitizing alteration; benefit across TKI generations
L858R FLAURA subgroup PFS HR 0.51 (0.36–0.71) [15] Established sensitizing alteration; may differ biologically but clear osimertinib benefit
G719X Afatinib ORR 77.8%, 14/18 [21] Drug-dependent uncommon sensitizing variant; small sample
L861Q Afatinib ORR 56.3%, 9/16 [21] Intermediate sensitivity; caution extrapolating from common mutations
S768I Afatinib ORR 100%, 8/8 [21] Highly imprecise estimate from very small subgroup
EGFR exon 20 insertion PAPILLON: ORR 73% with amivantamab–chemotherapy vs 47% with chemotherapy [22] Biologically distinct; conventional sensitizing-mutation TKI evidence does not apply uniformly
Acquired T790M / other resistance Resistance mechanism determines subsequent therapy [23] Requires rebiopsy or plasma/tissue profiling at progression
Histopathological subtype associations with EGFR variants
A 206-resection-specimen series classified invasive adenocarcinomas as lepidic (16), papillary (58), acinar (82), solid (40), micropapillary (5), mucinous (4) and fetal (1). EGFR mutation frequencies were 68.8%, 70.7%, 69.5%, 22.5%, 80.0% and 25.0%, respectively, across the first six categories [9]. The micropapillary point estimate arose from only five tumours and should not be treated as precise. An independent pooled pathology literature analysis found acinar histology to be most prevalent (34.7%), followed by papillary (22.9%), lepidic (18.9%), solid (13.6%) and micropapillary (6.3%) [10]. Different inclusion and classification rules limit direct comparisons.
Other pathological series have associated EGFR variants with lepidic, acinar, papillary or micropapillary growth and relatively lower frequency in solid-predominant or mucinous tumors [11,12,24]. These findings are associations in sampled populations; their positive and negative predictive values vary with geographic prevalence and clinical selection. Any morphologic pattern may still harbor an actionable mutation, particularly in limited biopsy specimens where the predominant whole-tumour pattern cannot be assigned reliably.
Table 2. Histological correlates of EGFR mutations
Growth pattern EGFR mutation frequency Principal interpretation
Lepidic 68.8% (11/16) Often associated with sensitizing EGFR variants
Papillary 70.7% (41/58) Frequent EGFR mutation; variable clinicopathological prognosis
Acinar 69.5% (57/82) Common pattern with substantial EGFR enrichment
Solid 22.5% (9/40) Lower EGFR prevalence in this series; may indicate adverse prognosis
Micropapillary 80.0% (4/5) Very small denominator; marked uncertainty
Mucinous 25.0% (1/4) EGFR mutations less common; evaluate other oncogenic drivers
Histological pattern as a treatment-response modifier
A retrospective cohort of 134 postoperative recurrent EGFR-mutated lung adenocarcinomas included 61 patients treated with first-line EGFR-TKI and fully evaluable histology. Solid-predominant tumors had significantly shorter TKI-associated PFS and OS than non-solid tumors, including a reported median PFS of 7.7 months in the solid group [25]. This suggests a potentially adverse prognostic morphology in a molecularly selected population, but the small sample, historical TKI exposure, surgical selection and retrospective design prevent definitive predictive attribution.
Solid and micropapillary architectural components may reflect invasive biology, higher-grade differentiation and intratumour heterogeneity. Conversely, lepidic-predominant tumors often present earlier and have a more favorable natural history. Therefore, an association between architecture and survival after TKI treatment may be confounded by stage, tumour burden, comutations, transformation or disease kinetics [6,7,11,25]. No high-certainty randomized evidence shows that selecting a different EGFR TKI solely because of a histological predominant pattern improves survival.
Uncommon variants and resistance
In the pooled LUX-Lung 2/3/6 afatinib analysis, the objective response among major uncommon variants was 71.1% overall, with variant-specific responses ranging from 56.3% for L861Q to 100% for S768I [21]. Conventional EGFR exon 20 insertions are generally less sensitive to many earlier TKIs, whereas PAPILLON evaluated first-line amivantamab plus chemotherapy and demonstrated superior responses versus chemotherapy [22]. In a real-world uncommon-variant cohort, ORR differed across first-generation inhibitors, afatinib and chemotherapy (29.6%, 59.5% and 30.8% in specified groups), but treatment allocation was nonrandom [25].
Acquired resistance can occur through secondary EGFR substitutions, MET amplification, bypass pathway activation, epithelial–mesenchymal transition or small-cell transformation. Resistance mechanisms can be heterogeneous within a tumour and across metastatic sites; repeat molecular testing at progression is therefore more actionable than reassessing morphology alone [23,26].
Table 3. Evidence domains, certainty and implications for clinical practice
Evidence domain Strength / limitation Practice implication
Common EGFR variants and first-line osimertinib Randomized phase III evidence [13–15] Treat based on molecularly confirmed mutation subtype
Ex19del versus L858R interaction Subgroup effects; limited formal interaction evidence Avoid claims of proven different relative treatment benefit
Histology–EGFR prevalence Resection-series and pooled pathology associations [9–12] Morphology can raise suspicion but cannot replace sequencing
Solid architecture and TKI outcome Small retrospective EGFR-mutant TKI cohort [24] Potential adverse prognostic marker, not validated treatment selector
G719X, L861Q and S768I Small post hoc afatinib cohorts [21] Interpret exact variant and compound mutation configuration
Exon 20 insertion Molecularly selected randomized treatment evidence [22] Avoid extrapolation from classical sensitizing variants
Resistance profiling Biological and clinical observational evidence [23,27] Consider tissue/plasma genotyping at progression
Comparative efficacy across treatment generations. The earlier IPASS, NEJ002, WJTOG3405, EURTAC, OPTIMAL and LUX-Lung trials established targeted EGFR inhibition against chemotherapy in selected or molecularly confirmed populations [29–35]. These comparisons supported clinical actionability of common activating mutations but did not establish that predominant morphology could substitute for molecular testing. Subsequent FLAURA, FLAURA2 and MARIPOSA findings further changed the expected efficacy of first-line treatment [13–18].
Variant-specific heterogeneity. A pooled survival analysis from LUX-Lung 3 and 6 separated exon 19 deletions from L858R when interpreting overall survival [36]. The ARCHER 1050 trial compared dacomitinib with gefitinib among common mutation carriers [37]. In KCSG-LU15-09, uncommon G719X, L861Q and S768I alterations were studied with osimertinib; the prospective UNICORN study likewise found activity in selected uncommon variants. These observations support variant-level molecular characterization rather than a binary mutant-versus-wild-type classification [38,39].
Treatment-response interaction and histology. Predominant architecture can be related to prognosis, grade and EGFR mutation prevalence; however, proof of a histology-by-treatment interaction requires mutation-stratified comparisons with sufficient adjustment. Solid-predominant growth was associated with shorter TKI benefit in a retrospective recurrent-disease cohort [24], but stage, invasive biology, sampled area and treatment selection may contribute to the association. Larger mutation-subtype datasets show variable outcomes between common and uncommon classes [40].
Reporting across PRISMA domains. The evidence differed by trial design, stage, EGFR assay, whole-section versus biopsy morphology, prespecified subgroup definitions and follow-up. Comparative treatment estimates were consistent with molecularly determined drug sensitivity, while pathology-specific estimates were more variable and frequently observational. Limited direct histology-by-EGFR subtype interaction tests and incomplete confounder adjustment restricted any quantitative joint prediction model.
DISCUSSION
Principal interpretation
The clearest association with TKI effectiveness is molecular rather than architectural. Exon 19 deletions and L858R both predict substantial sensitivity to osimertinib and other active EGFR-directed treatments, whereas some uncommon variants and exon 20 insertions require distinct strategies. Pathological architecture is complementary information: lepidic, acinar and papillary tumors are frequently EGFR-mutant in selected surgical series; solid growth has been linked to less favorable outcomes even after sensitizing mutations are confirmed [9–15,21,22,24].
Why genotype and morphology do not map one-to-one
Mutation formation precedes and interacts with tumour evolution, but architecture is influenced by additional genomic alterations, stromal factors, anatomic growth and sampling. A mixed adenocarcinoma may have a minor solid or micropapillary component missed on needle biopsy. More importantly, treatment resistance may arise from comutations or histological transformation without a change in the original sensitizing EGFR variant. Therefore, phenotype–genotype associations cannot support withholding NGS from tumors with seemingly unfavorable morphology [6,11,23,27].
Implications for diagnostic workflow
Pathological diagnosis should specify the tumour type, available architectural features and grade where supported by the specimen; advanced nonsquamous NSCLC should undergo comprehensive molecular testing regardless of smoking history or morphology. EGFR reports should identify the exact variant and compound alterations rather than record only “EGFR-positive.” For rare variants, molecular nomenclature, exon location, allelic context and coexisting alterations should be reviewed. Plasma ctDNA can supplement tissue when appropriate, but a negative plasma result does not exclude a targetable tumor variant [3,4,27].
Limitations and future research
The evidence base combines mutation-stratified randomized TKI trials with resection-based histology correlation studies and smaller retrospective treated cohorts. Differences in stage, ethnicity, fixation, predominant-pattern adjudication, TKI generation and time of biopsy limit comparability. There are few studies jointly evaluating exact EGFR subtype, whole-tumor growth pattern and matched TKI outcomes with multivariable interaction analysis. Future prospective registries should use harmonized WHO pathology reporting, broad NGS, blinded central histology review, longitudinal resistance profiling and predefined mutation-by-morphology interaction tests.
CONCLUSION
Principal interpretation
The clearest association with TKI effectiveness is molecular rather than architectural. Exon 19 deletions and L858R both predict substantial sensitivity to osimertinib and other active EGFR-directed treatments, whereas some uncommon variants and exon 20 insertions require distinct strategies. Pathological architecture is complementary information: lepidic, acinar and papillary tumors are frequently EGFR-mutant in selected surgical series; solid growth has been linked to less favorable outcomes even after sensitizing mutations are confirmed [9–15,21,22,24].
Why genotype and morphology do not map one-to-one
Mutation formation precedes and interacts with tumour evolution, but architecture is influenced by additional genomic alterations, stromal factors, anatomic growth and sampling. A mixed adenocarcinoma may have a minor solid or micropapillary component missed on needle biopsy. More importantly, treatment resistance may arise from comutations or histological transformation without a change in the original sensitizing EGFR variant. Therefore, phenotype–genotype associations cannot support withholding NGS from tumors with seemingly unfavorable morphology [6,11,23,27].
Implications for diagnostic workflow
Pathological diagnosis should specify the tumour type, available architectural features and grade where supported by the specimen; advanced nonsquamous NSCLC should undergo comprehensive molecular testing regardless of smoking history or morphology. EGFR reports should identify the exact variant and compound alterations rather than record only “EGFR-positive.” For rare variants, molecular nomenclature, exon location, allelic context and coexisting alterations should be reviewed. Plasma ctDNA can supplement tissue when appropriate, but a negative plasma result does not exclude a targetable tumor variant [3,4,27].
Limitations and future research
The evidence base combines mutation-stratified randomized TKI trials with resection-based histology correlation studies and smaller retrospective treated cohorts. Differences in stage, ethnicity, fixation, predominant-pattern adjudication, TKI generation and time of biopsy limit comparability. There are few studies jointly evaluating exact EGFR subtype, whole-tumor growth pattern and matched TKI outcomes with multivariable interaction analysis. Future prospective registries should use harmonized WHO pathology reporting, broad NGS, blinded central histology review, longitudinal resistance profiling and predefined mutation-by-morphology interaction tests.
REFERENCES
1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. doi:10.1056/NEJMoa040938.
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. doi:10.1126/science.1099314.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–13311. doi:10.1073/pnas.0405220101.
4. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–346. doi:10.1093/jnci/dji055.
5. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–792. doi:10.1056/NEJMoa044238.
6. Travis WD, Brambilla E, Noguchi M, et al. International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–285. doi:10.1097/JTO.0b013e318206a221.
7. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–1260. doi:10.1097/JTO.0000000000000630.
8. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022;17:362–387. doi:10.1016/j.jtho.2021.11.003.
9. Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. 2015. PMID:25550848. https://pubmed.ncbi.nlm.nih.gov/25550848/.
10. Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: a systematic literature review and pooled-data analysis. 2019. PMID:30833014. https://pubmed.ncbi.nlm.nih.gov/30833014/.
11. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the IASLC/ATS/ERS classification. 2014. PMID:24571650. https://pubmed.ncbi.nlm.nih.gov/24571650/.
12. Correlations between EGFR mutation status and clinicopathological features of clinical stage I lung adenocarcinoma. 2015. PMCID:PMC4620834. https://pmc.ncbi.nlm.nih.gov/articles/PMC4620834/.
13. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–125. doi:10.1056/NEJMoa1713137.
14. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. doi:10.1056/NEJMoa1913662.
15. Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial. Clin Cancer Res. 2019;25:6644–6652. doi:10.1158/1078-0432.CCR-19-1126.
16. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935–1948. doi:10.1056/NEJMoa2306434.
17. Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024. doi:10.1056/NEJMoa2403614.
18. Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025. doi:10.1056/NEJMoa2503001.
19. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
20. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
21. Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced NSCLC harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, 3, and 6. Lancet Oncol. 2015;16:830–838. PMID:26051236.
22. Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389:2039–2051. doi:10.1056/NEJMoa2306441.
23. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73. doi:10.1371/journal.pmed.0020073.
24. Solid-predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. 2013. PMID:23974272. https://pubmed.ncbi.nlm.nih.gov/23974272/.
25. EGFR uncommon alterations in advanced NSCLC and structural insights into sensitivity to diverse tyrosine kinase inhibitors. 2022. PMCID:PMC9523264. https://pmc.ncbi.nlm.nih.gov/articles/PMC9523264/.
26. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. doi:10.1126/scitranslmed.3002003.
27. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib in advanced NSCLC. J Clin Oncol. 2016;34:3375–3382. doi:10.1200/JCO.2016.66.7162.
28. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–640. doi:10.1056/NEJMoa1612674.
29. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. doi:10.1056/NEJMoa0810699.
30. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. doi:10.1056/NEJMoa0909530.
31. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC). Lancet Oncol. 2012;13:239–246. doi:10.1016/S1470-2045(11)70393-X.
32. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405). Lancet Oncol. 2010;11:121–128. doi:10.1016/S1470-2045(09)70364-X.
33. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802). Lancet Oncol. 2011;12:735–742. doi:10.1016/S1470-2045(11)70184-X.
34. Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–3334. doi:10.1200/JCO.2012.44.2806.
35. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6). Lancet Oncol. 2014;15:213–222. doi:10.1016/S1470-2045(13)70604-1.
36. Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–151. PMID:25589191.
37. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–1466. PMID:28958502.
38. Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38:488–495. doi:10.1200/JCO.19.00931.
39. Okuma Y, Kubota K, Shimokawa M, et al. First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial. JAMA Oncol. 2024. doi:10.1001/jamaoncol.2023.5013.
40. Clinical impact of EGFR mutation subtypes on treatment outcomes in advanced non-small cell lung cancer: an Austrian real-world study. 2026. PMCID:PMC12838531. https://pmc.ncbi.nlm.nih.gov/articles/PMC12838531/.
Recommended Articles
Original Article
Comparison of Dexmedetomidine and Esmolol for Controlled Hypotension and Surgical-Field Quality During Functional Endoscopic Sinus Surgery (FESS)